NATIONAL NEWS

FDA plans ultra-fast review of three psychedelic drugs following Trump directive

Apr 24, 2026, 7:04 AM

FILE - A grower cuts psilocybin mushrooms to prepare for distribution in Springfield, Ore., Monday,...

FILE - A grower cuts psilocybin mushrooms to prepare for distribution in Springfield, Ore., Monday, Aug. 14, 2023. (AP Photo/Craig Mitchelldyer, File)
Credit: ASSOCIATED PRESS

(AP Photo/Craig Mitchelldyer, File)

WASHINGTON (AP) — The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest indication of the Trump administration’s commitment to the experimental treatment approach.

President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed access and loosen restrictions on psychedelics, a class of hallucinogenic drugs which remain illegal under federal law.

The FDA said it awarded priority review vouchers to two companies studying psilocybin — the active ingredient in magic mushrooms — for hard-to-treat forms of depression. A third company received a voucher for methylone, a drug related to MDMA, for post-traumatic stress disorder. The FDA did not name the companies in a press release announcing the vouchers.

The vouchers don’t guarantee approval, but instead mean that regulators will aim to shorten their review timeline from a period of months to weeks.

The recent moves on psychedelics reflect growing popular support for the mind-altering substances among Trump’s supporters, including combat veterans and followers of the Make America Healthy Again movement spearheaded by Health Secretary Robert F. Kennedy Jr.

Last July, Kennedy told members of Congress his department aimed to make psychedelics available for hard-to-treat psychiatric conditions within one year. Some of Kennedy’s top allies and staffers are proponents of the drugs.

Calley Means, a former Kennedy campaign staffer now serving as a senior health adviser, has previously written about the “mind-blowing” power of psychedelics and his plans to invest in companies developing the drugs.

FDA’s special treatment for psychedelics is likely to renew scrutiny of its program for speeding up drug reviews, known as the Commissioner’s National Priority Voucher program.

Democratic members of Congress have noted that vouchers have gone to companies that are politically favored by the White House, including those that have agreed to cut prices on their medications.

In a separate move, the FDA authorized initial testing of a drug related to ibogaine, a powerful psychedelic made from an African shrub, for people with alcohol use disorder. Ibogaine is known to sometimes cause dangerous heart rhythms but has been embraced by combat veterans as a way to treat trauma and addiction.

The drugmaker, DemeRx, is led by a Florida-based researcher who first began studying ibogaine in the 1990s, before federal health officials pulled public funding for the work. DemeRx’s drug is a metabolite of ibogaine, and the company says it doesn’t carry the same risks as the original drug.

Saturday’s White House event on psychedelics suggested Trump’s political allies had a role in pushing the drugs to the top of his agenda.

Joe Rogan, the podcaster who appeared at the Oval Office event, said he texted Trump about the psychedelic ibogaine, which he’s repeatedly discussed on his show. According to Rogan, the president quickly responded: “Sounds great. Do you want FDA approval? Let’s do it.”

Rogan’s endorsement of Trump days before the November 2024 election was seen by White House aides as a key factor in his election victory.

On his show earlier this week, Rogan said he learned about ibogaine from his friend Ed Clay, a mixed martial arts trainer and entrepreneur who runs retreats making use of it in Mexico.

Virtually all psychedelics, including LSD, psilocybin and MDMA are classified as Schedule I substances, a category for high-risk drugs that have no medically accepted use.

For decades, drugmakers steered clear of the substances due to the difficulties of studying drugs that are illegal under federal law.

But dozens of small drugmakers, many fueled by Silicon Valley investors, have recently jumped into the race to win FDA approval for various psychedelics. For example, tech billionaire Peter Thiel — who has made political donations to both Trump and Vice President JD Vance — has invested in AtaiBeckley, a company studying MDMA and other psychedelic compounds.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

National News

Associated Press

3 people shot, including 2 public safety officers, at New York City apartment complex

NEW YORK (AP) — Three people, including two public safety officers, were shot Monday at a New York City apartment complex, police said. Their injuries are not believed to be life-threatening. The suspected gunman remained barricaded after the shooting at the massive Co-op City complex in the Bronx, police said. Authorities advised people to avoid […]

12 minutes ago

FILE - Commerce Secretary Howard Lutnick speaks at a campaign rally, Oct. 13, 2026, in Wasilla, Ala...

Associated Press

Trump administration moves to block China from indirect access to American AI technology

WASHINGTON (AP) — The Trump administration on Monday issued new rules to restrict remote access to advanced U.S. computing chips and servers, marking the latest step to limit China’s abilities to use U.S. chips to train their best artificial intelligence models. The rule also was issued days after Nvidia co-founder Jensen Huang resigned as CEO […]

34 minutes ago

Federal Reserve Board Chairman Kevin Warsh speaks during a news conference at the Federal Reserve, ...

Associated Press

Warsh grapples with AI’s potential economic impact, steers clear of its inflation risk

WASHINGTON (AP) — Artificial intelligence could accelerate innovation and usher in an era of faster economic growth, Federal Reserve Chairman Kevin Warsh said Monday in remarks that underscored his generally optimistic outlook on the new technology, a view at odds with many of his colleagues. At the same time, Warsh acknowledged that the development of […]

42 minutes ago

Associated Press

Person of interest taken into custody for questioning after bomb found at Illinois ethanol plant

A person of interest was taken into custody for questioning Monday morning related to a bomb located at an ethanol plant in central Illinois, Peoria police said. The person was taken into custody Monday morning at the BioUrja Renewables facility in Peoria, the same place where an explosive device was found on Friday, Peoria police […]

2 hours ago

FILE - The Supreme Court is seen at day's end in Washington, Oct. 1, 2026. (AP Photo/J. Scott Apple...

Associated Press

Supreme Court declines to hear challenge to Maryland ‘sensitive places’ gun law

WASHINGTON (AP) — The Supreme Court declined Monday to consider a challenge to a Maryland law restricting where people can carry guns. The law prohibits carrying concealed weapons into schools, mass transit, bars and other areas deemed sensitive places. The high court declined the case without comment. But Justice Clarence Thomas wrote to say he’s […]

2 hours ago

President Donald Trump speaks with reporters before departing on Marine One from the South Lawn of ...

Associated Press

Third American aircraft carrier arrives in the Middle East as Trump keeps options open in Iran war

WASHINGTON (AP) — The USS Theodore Roosevelt has arrived in the Middle East, once again bringing the total number of U.S. aircraft carriers in the Middle East to three — an unusually high number. A U.S. official, who spoke on condition of anonymity to discuss sensitive military operations, on Monday confirmed the carrier’s arrival in […]

2 hours ago

FDA plans ultra-fast review of three psychedelic drugs following Trump directive